HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDAC Veterans Join DSaRM Advisory Panel For DXM Safety Meeting

This article was originally published in The Tan Sheet

Executive Summary

The presence of Nonprescription Drug Advisory Committee members as temporary voters on FDA's Drug Safety and Risk Management Advisory Committee brings expertise on OTC issues and a potential industry advocate to the Sept. 14 meeting on dextromethorphan abuse

You may also be interested in...



FDA Panel Says Leave DXM Unscheduled For Now, Urges Congressional Action

Dextromethorphan likely will escape scheduling as a controlled substance in the near term, but manufacturers and lawmakers should push efforts to curb abuse to keep the cough suppressant available OTC in the long run

DXM Panel Proposes Augmenting, Improving Education To Curb Abuse

Members of an FDA panel tipped their hats to the Consumer Healthcare Product Association's efforts to reduce dextromethorphan abuse, but floated enhancements to the program

FDA Risk Panel DXM Meeting Raises Stakes on Age Restriction Movement

A Drug Safety and Risk Management Advisory Committee meeting scheduled for Sept. 14 on the potential for abuse of the cough suppressant dextromethorphan could bring the OTC industry's next regulatory nightmare

Related Content

Topics

UsernamePublicRestriction

Register

RS135482

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel